Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self-subcutaneous unfractionated heparin calcium injection: A case report

• Published in: Molecular and clinical oncology Vol. 14; no. 5; p. 104
• Main Authors: Yagi, Toshinari, Nakamura, Harumi, Wakamatsu, Toru, Imura, Yoshinori, Tamiya, Hironari, Sabe, Hideaki, Yamashita, Katsunari, Watanabe, Makiyo, Takenaka, Satoshi
• Format: Journal Article
• Language: English
• Published: England Spandidos Publications 01.05.2021; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Angiosarcoma; Anticoagulants; Cancer; Carboplatin; Case reports; Chemotherapy; Cloning; Danaparoid; Disseminated intravascular coagulation; Eribulin mesylate; Health aspects; Laboratories; Metastasis; Patients; Prognosis; Radiation therapy; Sodium; Thrombosis; Tranexamic acid; Tumors; Japan; heparin; angiosarcoma; disseminated intravascular coagulation
• ISSN: 2049-9450; 2049-9469
• DOI: 10.3892/mco.2021.2266

Angiosarcoma is a rare sarcoma with a poor prognosis and is prone to disseminated intravascular coagulation (DIC), where DIC often interferes with chemotherapy. Primary angiosarcoma of the breast (PASB) is a type of angiosarcoma that is located in mammary parenchyma and is not associated with radiation exposure. The current study reported a 47-year-old female with DIC associated with PASB. The DIC of the patient relapsed during mono-chemotherapy with paclitaxel (PTX) after first-line anticoagulant therapy using thrombomodulin-α. The second-line danaparoid sodium therapy, followed by self-subcutaneous injection of unfractionated heparin calcium (UFH), resulted in long-term stabilization of DIC. Under this second-line anticoagulant therapy, the patient continued chemotherapy and chemoradiotherapy for >13 months in the outpatient setting without impairment of quality of life. The present case suggested that self-subcutaneous injections of UFH may be a useful therapeutic option for long-term control of DIC associated with PASB. However, further prospective clinical trails are needed to verify the efficacy of self-subcutaneous injection of UFH in similar settings.